NDA 020989 · Cosette
Evoxac
Cevimeline Hydrochloride · Oral
NovelLast checked: Nov 19, 2026Latest source record: Nov 1, 2013 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2000
Jan 11, 2000
Approved uses
1
Original approval plus efficacy supplements
Registered trials
6
1 Phase 3, 0 recruiting
FAERS reports
2,791
1,462 serious, 109 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 9, 2026.
EVOXAC is indicated for the treatment of symptoms of dry mouth in adults with Sjögren’s disease. EVOXAC is a cholinergic agonist indicated for the treatment of symptoms of dry mouth in adults with Sjögren’s disease. ( 1 )
Mechanism: Cevimeline is a cholinergic agonist which binds to muscarinic receptors in various exocrine glands.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- EVOXAC · CEVIMELINE HYDROCHLORIDE 30MG · CAPSULE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Cevimeline" as an intervention, any sponsor and status, largest first.
- Evaluation of BTV100 in Subjects With Dry Eye DiseasePivotal-lookingCompleted
BioTheraVision, Inc.Industry
NCT06543303 · 123 participants · Start Dec 31, 2024 · Primary completion Jan 14, 2026
Drug: BTV100 Low dose; BTV100 Mid dose and 2 more · For: Dry Eye
Sites: Doncaster East, Australia; Sydney, Australia; Kaohsiung City, Taiwan · 6 sites in all
American Academy of Otolaryngology-Head and Neck Surgery FoundationAcademic, hospital or other
NCT00466388 · 54 participants · Start May 2007 · Primary completion Jun 2009
Drug: Cevimeline · For: Xerostomia
Sites: Colorado Springs, Colorado; Urbana, Illinois; Kansas City, Kansas · 7 sites in all
Roxane LaboratoriesIndustry
NCT01903109 · 27 participants · Start Feb 2009 · Primary completion Feb 2009
Drug: Cevimeline · For: Dry Mouth
Sites: Las Vegas, Nevada
Roxane LaboratoriesIndustry
NCT01903122 · 26 participants · Start Feb 2009 · Primary completion Feb 2009
Drug: Cevimeline · For: Dry Mouth
Sites: Las Vegas, Nevada
University of KentuckyAcademic, hospital or other
NCT01690052 · 15 participants · Start Jan 2009 · Primary completion Jun 2010
Drug: Cevimeline; Pilocarpine · For: Dry Mouth
Sites: Lexington, Kentucky
- Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck CancerPivotal-lookingCompleted
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT00017511 · Start Jun 2001 · Primary completion Mar 2003
Drug: cevimeline hydrochloride · For: Head and Neck Cancer; Oral Complications; Radiation Toxicity
Sites: Birmingham, Alabama; Mobile, Alabama; Tucson, Arizona · 71 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective218
- headache184
- nausea171
- diarrhoea169
- fatigue162
- dyspnoea146
- pain133
- arthralgia124
- off label use111
- fall109
- malaise100
- dizziness97
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 30 |
| 2005 | 29 |
| 2006 | 31 |
| 2007 | 39 |
| 2008 | 41 |
| 2009 | 54 |
| 2010 | 68 |
| 2011 | 74 |
| 2012 | 97 |
| 2013 | 123 |
| 2014 | 105 |
| 2015 | 174 |
| 2016 | 251 |
| 2017 | 164 |
| 2018 | 177 |
| 2019 | 196 |
| 2020 | 151 |
| 2021 | 125 |
| 2022 | 152 |
| 2023 | 133 |
| 2024 | 196 |
| 2025 | 181 |
| 2026 | 200 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Evoxac (Cevimeline HCl)
2024 spending
$1.0M
Beneficiaries
183
797 claims
Per beneficiary
$5,539
$7.69 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $291,979 |
| 2023 | $1,166,165 |
| 2024 | $1,013,650 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Neuropharmacology of Cevimeline and Muscarinic Drugs-Focus on Cognition and Neurodegeneration.
Oleksak P, Novotny M, Patocka J, et al. · Int J Mol Sci 2021 · Systematic Review
- Effect of cevimeline on salivary components in patients with Sjögren syndrome.
Suzuki K, Matsumoto M, Nakashima M, et al. · Pharmacology 2005 · Clinical Trial
- Cholinergic medication for antipsychotic-induced tardive dyskinesia.
Tammenmaa-Aho I, Asher R, Soares-Weiser K, et al. · Cochrane Database Syst Rev 2018 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Efficacy of cevimeline vs. pilocarpine in the secretion of saliva: a pilot study.
Brimhall J, Jhaveri MA, Yepes JF · Spec Care Dentist 2013 · Comparative Study, Randomized Controlled Trial
- Efficacy prediction of cevimeline in patients with Sjögren's syndrome.
Yamada H, Nakagawa Y, Wakamatsu E, et al. · Clin Rheumatol 2007 · Clinical Trial
- Cholinergic medication for neuroleptic-induced tardive dyskinesia.
Tammenmaa IA, McGrath JJ, Sailas E, et al. · Cochrane Database Syst Rev 2002 · Systematic Review
Sponsor: Cosette
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.